The Drug Information Association (DIA) India is organizing its flagship PV conference “PV –Fast Forward”-Technology, Pace and Priority. The event will be held on March 24 and 25, 2017 at the Hotel The Lalit, Mumbai.
The two-day event will have Moin Don, CEO and President, PVCON as The Chair and Krishna Bahadur Singh, senior vice president, safety& risk management, business unit, ARIS Global LLC & Representative Director, AGKK, Tokyo, Japan as the vice chair.
Programme will highlight Label Management & Risk Management, Automation in PV, Compliance Management in PV, Latest Regulations in PV, advanced Technologies to Handle Safety Data, delve on the importance of technology in bringing about higher patient safety.
At the end of the conference, the participants should be able to comprehend multiple facets of global drug safety concepts along with insights on Indian Pharmacovigilance, understand how new technologies can help in improving adverse event reporting and processing of safety data. In addition, they will be able to discuss the advancements in pharmacovigilance in the European Union and how it influences the global drug safety, stated Manoj Trivedi, senior manager, business development, DIA (India) Private Limited.
According to the organisers, technological advancements are rapidly impacting the way pharmacovigilance obligations will be fulfilled by marketing authorization holders. The modus operandi of conducting pharmacovigilance operations is expected to change significantly by the year 2020. Automation, artificial intelligence, machine learning, cognitive computing, proactive pharmacovigilance are shaping the new paradigm of the safety world.
“Achieving compliance at a lower cost and higher quality is much closer as a goal today than it was ever before. Therefore PV fast forward is a meeting of minds provides an opportunity to cross learn. The conference will ensure enough opportunity to interact with speakers and colleagues from the entire spectrum of the pharmacovigilance domain in India,” said the organisers.
Programme Committee comprises Achint Kumar Gupta, EU QPPV, Safety & Benefit-Risk Management, Biogen, Jamal Anwar Baig, Country Head, Pharmacovigilance, Merck Sharp & Dohme, J Vijay Venkataraman, managing director & CEO, Oviya MedSafe, Mangesh Kulkarni, headp Pharmacovigilance, TCS, Rajesh Jain, director operations & business solutions, Cognizant, Retesh Kumar, senior business consultant and Engagement Lead, Tata Consultancy Services G Parthasarathi, Dean, Faculty of Pharmacy, JSS University, Vivek Ahuja, VP Global , Pharmacovigilance, ArisGlobal.